Synonyms: NA-1 | Tat-NR2B9c
Compound class:
Peptide
Comment: Nerinetide (NA-1) is a peptide that was designed to target the PDZ domain of the PSD-95 protein (gene symbol DLG4) [1] to prevent its interaction with N-methyl-D-aspartate receptors (NMDARs) and neuronal nitric oxide synthase (nNOS) and block assembly of the tri-peptide complex that is a therapeutic target for the treatment of acute ischemic stroke [2-3]. Structurally, nerinetide is a 20 amino acid linear peptide that comprises nine residues derived from the COOH-terminal of the NR2B NMDAR (GluN2B; GRIN2B; that directly interacts with PSD-95's PDZ2 domain) fused to 11 amino acid cell-membrane transduction domain of the HIV-1 Tat protein (Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg; to create a cell permeable peptide). The NMDAR/nNOS/PSD-95 complex mediates neurotoxic signaling, and disruption of this function provides a neuroprotective effect that ameliorates ischemic brain damage, without inducing the negative consequences that can arise through NMDAR blockade.
|
|
References |
1. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, Wang YT, Salter MW, Tymianski M. (2002)
Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science, 298 (5594): 846-50. [PMID:12399596] |
2. Fan J, Vasuta OC, Zhang LY, Wang L, George A, Raymond LA. (2010)
N-methyl-D-aspartate receptor subunit- and neuronal-type dependence of excitotoxic signaling through post-synaptic density 95. J Neurochem, 115 (4): 1045-56. [PMID:20831617] |
3. Zhou L, Li F, Xu HB, Luo CX, Wu HY, Zhu MM, Lu W, Ji X, Zhou QG, Zhu DY. (2010)
Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95. Nat Med, 16 (12): 1439-43. [PMID:21102461] |